Skip to main content
. Author manuscript; available in PMC: 2018 Feb 28.
Published in final edited form as: Sci Transl Med. 2017 Aug 30;9(405):eaam5441. doi: 10.1126/scitranslmed.aam5441

Fig. 5. Ixolaris potently blocks TF activity but not protein expression in activated monocytes from HIV+ patients and chronically SIV-infected NHPs.

Fig. 5

(A) Tissue factor functional activity in vitro measured by Factor Xa formation in elutriated monocyte cultures from healthy donors stimulated with LPS and treated with indicated doses of Ixolaris (n=5). Data represent percentage of the positive control (LPS 1μg/ml without Ixolaris). TF activity upon treatment with Ixolaris was compared between (B) healthy controls (n=12) and unmatched ART-naïve HIV+ (n=10) patients and those who achieved ART-induced virological suppression (post-ART; n=10) as well as between (C) chronically SIV-infected PTMs (n=6) and AGMs (n=6). (D) Representative plots of intracellular IL-6 and TNF-α production in monocytes from ART-naïve HIV+ individuals stimulated in the presence or absence of Ixolaris (left panel). Summary data showing frequency of TFpos monocytes as well as percent of cytokine producing monocytes in stimulated cultures treated or non-treated with Ixolaris (right panel). Data were analyzed using the Wilcoxon matched pairs test. * P<0.05, *** P<0.001.